Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts

Hepatology

Volumn 58, Issue 1, 2013, Pages 43-53

  Schieck, Alexa ^a   Schulze, Andreas ^a   Gähler, Caroline ^a   Müller, Thomas ^a   Haberkorn, Uwe ^a   Alexandrov, Alexander ^b   Urban, Stephan ^a   Mier, Walter ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Myr GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROLIPOAMIDE DEHYDROGENASE; LIPOPEPTIDE; RECEPTOR; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DOG; GLOMERULUS FILTRATION; HAPLORHINI; HEPATITIS B; HEPATITIS B VIRUS; IN VIVO STUDY; LIVER; LIVER CELL; MEMBRANE FUSION; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; ORGAN DISTRIBUTION; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SERUM FACTOR; VIRAL TROPISM; VIRUS INHIBITION;

ANIMALS; DOGS; FEMALE; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; LIPOPEPTIDES; LIVER; MACACA FASCICULARIS; MICE; RATS; RECEPTORS, VIRUS; VIRAL ENVELOPE PROTEINS;

EID: 84879606185     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26211     Document Type: Article

References (32)

1. Cornberg M, Jaroszewicz J, Manns MP, Wedemeyer H. Treatment of chronic hepatitis B. Minerva Gastroenterol Dietol 2010; 56: 451-465.
2. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009; 137: 1593-1608.
3. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68.
4. Bruss V. Hepatitis B virus morphogenesis. World J Gastroenterol 2007; 13: 65-73.
5. Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. HEPATOLOGY 2007; 46: 1759-1768.
6. Engelke M, Mills K, Seitz S, Simon P, Gripon P, Schnolzer M, et al. Characterization of a hepatitis B and hepatitis delta virus receptor binding site. HEPATOLOGY 2006; 43: 750-760.
7. Gripon P, Cannie I, Urban S. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol 2005; 79: 1613-1622.
8. LeSeyec J, Chouteau P, Cannie I, Guguen-Guillouzo C, Gripon P. Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J Virol 1999; 73: 2052-2057.
9. Gripon P, LeSeyec J, Rumin S, Guguen-Guillouzo C. Myristylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology 1995; 213: 292-299.
10. LeDuff Y, Blanchet M, Sureau C. The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent. J Virol 2009; 83: 12443-12451.
11. Blanchet M, Sureau C. Infectivity determinants of the hepatitis B virus pre-S domain are confined to the N-terminal 75 amino acid residues. J Virol 2007; 81: 5841-5849.
12. Leistner CM, Gruen-Bernhard S, Glebe D. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell Microbiol 2008; 10: 122-133.
13. Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH. Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus. J Virol 2003; 77: 9511-9521.
14. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of the host response to hepatitis B virus infection. Proc Natl Acad Sci U S A 2004; 101: 6669-6674.
15. Urban S, Schulze A, Dandri M, Petersen J. The replication cycle of hepatitis B virus. J Hepatol 2010; 52: 282-284.
16. Asabe S, Wieland SF, Chattopadhyay PK, Roederer M, Engle RE, Purcell RH, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 2009; 83: 9652-9662.
17. Gripon P, Rumin S, Urban S, LeSeyec J, Glaise D, Cannie I, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci U S A 2002; 99: 15655-15660.
18. Sureau C. The use of hepatocytes to investigate HDV infection: the HDV/HepaRG model. Methods Mol Biol 2010; 640: 463-473.
19. Glebe D, Urban S, Knoop EV, Cag N, Krass P, Grun S, et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 2005; 129: 234-245.
20. Schulze A, Schieck A, Ni Y, Mier W, Urban S. Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction. J Virol 2010; 84: 1989-2000.
21. Petersen J, Dandri M, Mier W, Lutgehetmann M, Volz T, von WF, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008; 26: 335-341.
22. Meier A, Mehrle S, Weiss TS, Mier W, Urban S. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. HEPATOLOGY 2013; 58: 31-42.
23. Schieck A, Muller T, Schulze A, Haberkorn U, Urban S, Mier W. Solid-phase synthesis of the lipopeptide Myr-HBVpreS/2-78, a hepatitis B virus entry inhibitor. Molecules 2010; 15: 4773-4783.
24. Crim JW, Garczynski SF, Brown MR. Approaches to radioiodination of insect neuropeptides. Peptides 2002; 23: 2045-2051.
25. Barrera A, Guerra B, Notvall L, Lanford RE. Mapping of the hepatitis B virus pre-S1 domain involved in receptor recognition. J Virol 2005; 79: 9786-9798.
26. Mergler M, Dick F, Sax B, Weiler P, Vorherr T. The aspartimide problem in Fmoc-based SPPS. Part I. J Pept Sci 2003; 9: 36-46.
27. Martin PL, Weinbauer GF. Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions. Int J Toxicol 2010; 29: 552-568.
28. Lucifora J, Vincent IE, Berthillon P, Dupinay T, Michelet M, Protzer U, et al. Hepatitis B virus replication in primary macaque hepatocytes: crossing the species barrier toward a new small primate model. HEPATOLOGY 2010; 51: 1954-1960.
29. Alter MJ. Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003; 23: 39-46.
30. Walter E, Keist R, Niederost B, Pult I, Blum HE. Hepatitis B virus infection of tupaia hepatocytes in vitro and in vivo. HEPATOLOGY 1996; 24: 1-5.
31. Lutgehetmann M, Mancke LV, Volz T, Helbig M, Allweiss L, Bornscheuer T, et al. Humananized chimeric uPA mouse model to study hepatitis B and D virus interactions and preclinical drug evaluation. HEPATOLOGY 2012; 55: 685-694.
32. Dandri M, Lutgehetmann M, Volz T, Petersen J. Small animal model systems for studying hepatitis B virus replication and pathogenesis. Semin Liver Dis 2006; 26: 181-191.